主权项 |
1. A method for treating a patient with rheumatoid arthritis with one or more treatments selected from the group consisting of PLAQUENIL (or Hydroxychloroquine), Sulfasalazine, Methotrexate, ARAVA (or Leflunomide), Tumor Necrosis Factor-α inhibitors, Atabacept (or ORENCIA), Tocilizumab (or ACTEMRA), RITUXAN (or Rituximab), and Tofacitinib (or XELJANZ), which comprises:
i. Determining serum levels in the patient of a group of biomarkers comprising Vascular Cell Adhesion Molecule 1, Vascular Endothelial Growth Factor-A, Interleukin-6, Tumor Necrosis Factor Receptor Type 1, Matrix Metalloproteinase-1, Matrix Metalloproteinase-3, YKL-40, Leptin, Resistin, Serum Amyloid A, and C-Reactive Protein; ii. Identifying at least two biomarkers each one with at least 40% elevated serum level over control serum level, wherein if the at least two biomarkers with at least 40% elevated levels are:
1) Vascular Cell Adhesion Molecule 1 and Vascular Endothelial Growth Factor-A, selecting treatment with Tumor Necrosis Factor-α inhibitors;2) Vascular Cell Adhesion Molecule 1 and Interleukin-6, selecting treatment with one or more of ARAVA (Leflunomide) and Atabacept (ORENCIA);3) Vascular Cell Adhesion Molecule 1 and Tumor Necrosis Factor Receptor Type 1, selecting treatment with one or more of ARAVA (Leflunomide) and Tumor Necrosis Factor-α inhibitors;4) Vascular Cell Adhesion Molecule 1 and Matrix Metalloproteinase-1, selecting treatment with one or more of ARAVA (Leflunomide) and Tumor Necrosis Factor-α inhibitors;5) Vascular Cell Adhesion Molecule 1 and Matrix Metalloproteinase-3, selecting treatment with one or more of ARAVA (or Leflunomide), Tumor Necrosis Factor-α inhibitors and Atabacept (or ORENCIA);6) Vascular Cell Adhesion Molecule 1 and YKL-40, selecting treatment with Tumor Necrosis Factor-α inhibitors;7) Vascular Cell Adhesion Molecule 1 and Resistin, selecting treatment with Tumor Necrosis Factor-α inhibitors;8) Vascular Cell Adhesion Molecule 1 and Serum Amyloid A, selecting treatment with one or more of ARAVA (or Leflunomide) and Tumor Necrosis Factor-α;9) Vascular Cell Adhesion Molecule 1 and C-Reactive Protein, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Atabacept (or ORENCIA);10) Vascular Endothelial Growth Factor-A and Interleukin-6, selecting treatment with one or more of Sulfasalazine, Methotrexate and Tocilizumab (or ACTEMRA);11) Vascular Endothelial Growth Factor-A and Tumor Necrosis Factor Receptor Type 1, selecting treatment with one or more of Sulfasalazine and Tumor Necrosis Factor-α inhibitors;12) Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-1, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);13) Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-3, selecting treatment with one or more of Sulfasalazine, Methotrexate, Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);14) Vascular Endothelial Growth Factor-A and YKL-40, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);15) Vascular Endothelial Growth Factor-A and Resistin, selecting treatment with Tumor Necrosis Factor-α inhibitors;16) Vascular Endothelial Growth Factor-A and Serum Amyloid A, selecting treatment with one or more of Sulfasalazine, Methotrexate, Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);17) Vascular Endothelial Growth Factor-A and C-Reactive Protein, selecting treatment with one or more of Sulfasalazine, Methotrexate, Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);18) Interleukin-6 and Tumor Necrosis Factor Receptor Type 1, selecting treatment with one or more of Sulfasalazine and ARAVA (or Leflunomide);19) Interleukin-6 and Matrix Metalloproteinase-1, selecting treatment with one or more of ARAVA (or Leflunomide), Tocilizumab (or ACTEMRA) and Tofacitinib (or XELJANZ);20) Interleukin-6 and Matrix Metalloproteinase-3, selecting treatment with one or more of Sulfasalazine, Methotrexate, ARAVA (or Leflunomide), Atabacept (or ORENCIA), Tocilizumab (or ACTEMRA) and Tofacitinib (or XELJANZ);21) Interleukin-6 and YKL-40, selecting treatment with one or more of Tocilizumab (or ACTEMRA);22) Interleukin-6 and Serum Amyloid A, selecting treatment with one or more of PLAQUENIL (or Hydroxychloroquine), Sulfasalazine, Methotrexate, ARAVA (or Leflunomide) and Tocilizumab (or ACTEMRA);23) Interleukin-6 and C-Reactive Protein, selecting treatment with one or more of PLAQUENIL (or Hydroxychloroquine), Sulfasalazine, Methotrexate, Atabacept (or ORENCIA), Tocilizumab (or ACTEMRA) and RITUXAN (or Rituximab);24) Tumor Necrosis Factor Receptor Type 1 and Matrix Metalloproteinase-1, selecting treatment with one or more of ARAVA (or Leflunomide) and Tumor Necrosis Factor-α inhibitors;25) Tumor Necrosis Factor Receptor Type 1 and Matrix Metalloproteinase-3, selecting treatment with one or more of Sulfasalazine, ARAVA (or Leflunomide) and Tumor Necrosis Factor-α inhibitors;26) Tumor Necrosis Factor Receptor Type 1 and YKL-40, selecting treatment with Tumor Necrosis Factor-α inhibitors;27) Tumor Necrosis Factor Receptor Type 1 and Resistin selecting treatment with Tumor Necrosis Factor-α inhibitors;28) Tumor Necrosis Factor Receptor Type 1 and Serum Amyloid A, selecting treatment with one or more of Sulfasalazine, ARAVA (or Leflunomide) and Tumor Necrosis Factor-α inhibitors;29) Tumor Necrosis Factor Receptor Type 1 and C-Reactive Protein, selecting treatment with one or more of Sulfasalazine and Tumor Necrosis Factor-α inhibitors;30) Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3, selecting treatment with one or more of ARAVA (or Leflunomide), Tumor Necrosis Factor-α inhibitors, Tocilizumab (or ACTEMRA) and Tofacitinib (or XELJANZ);31) Matrix Metalloproteinase-1 and YKL-40, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);32) Matrix Metalloproteinase-1 and Resistin, selecting treatment with Tumor Necrosis Factor-α inhibitors;33) Matrix Metalloproteinase-1 and Serum Amyloid A, selecting treatment with one or more of ARAVA (or Leflunomide), Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);34) Matrix Metalloproteinase-1 and C-Reactive Protein, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);35) Matrix Metalloproteinase-3 and YKL-40, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);36) Matrix Metalloproteinase-3 and Resistin, selecting treatment with Tumor Necrosis Factor-α inhibitors;37) Matrix Metalloproteinase-3 and Serum Amyloid A, selecting treatment with one or more of Sulfasalazine, Methotrexate, ARAVA (or Leflunomide), Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);38) Matrix Metalloproteinase-3 and C-Reactive Protein, selecting treatment with one or more of Sulfasalazine, Methotrexate, Tumor Necrosis Factor-α inhibitors, Atabacept (or ORENCIA) and Tocilizumab (or ACTEMRA);39) YKL-40 and Resistin, selecting treatment with Tumor Necrosis Factor-α inhibitors;40) YKL-40 and Serum Amyloid A, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);41) YKL-40 and C-Reactive Protein, selecting treatment with one or more of Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA);42) Resistin and Serum Amyloid A, selecting treatment with Tumor Necrosis Factor-α inhibitors;43) Resistin and C-Reactive Protein, selecting treatment with Tumor Necrosis Factor-α inhibitors; and44) Serum Amyloid A and C-Reactive Protein, selecting treatment with one or more of PLAQUENIL (or Hydroxychloroquine), Sulfasalazine, Methotrexate, Tumor Necrosis Factor-α inhibitors and Tocilizumab (or ACTEMRA); and iii. Administering the treatment selected in step (ii) to the patient. |